Pulike Biological Engineering, Inc. (SHA:603566)

China · Delayed Price · Currency is CNY

10.53

+0.09 (0.86%)

Jul 15, 2026, 3:00 PM CST

-24.30% (1Y)

Market Cap	3.57B -24.9%
Revenue (ttm)	1.06B -2.3%
Net Income	172.82M +46.0%
EPS	0.50 +44.4%
Shares Out	341.92M
PE Ratio	20.83
Forward PE	20.88
Dividend	0.60 (5.84%)
Ex-Dividend Date	Jun 16, 2026

Volume	3,551,524
Open	10.44
Previous Close	10.44
Day's Range	10.37 - 10.65
52-Week Range	9.56 - 15.79
Beta	0.35
Analysts	Strong Buy
Price Target	15.44 (+46.63%)
Earnings Date	Aug 25, 2026

About SHA:603566

Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1995

Employees 1,519

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603566

Full Company Profile

Financial Performance

In 2025, SHA:603566's revenue was 1.09 billion, an increase of 4.54% compared to the previous year's 1.04 billion. Earnings were 184.99 million, an increase of 99.33%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 603566 stock is "Strong Buy." The 12-month stock price target is ¥15.44, which is an increase of 46.63% from the latest price.

Price Target

¥15.44

(46.63% upside)

Analyst Consensus: Strong Buy

Stock Forecasts